Aurobindo Pharma has announced the appointment of T. Vijaya Kumar as President, R&D (Specialty Drug Delivery).

Kumar holds Masters in Pharmacy (M.Pharma.), Post-Graduation in Pharmacy from Gulbarga University, Gulbarga (India) with a specialisation in Pharmaceutical Technology.

He has almost 30 years of experience in the pharmaceutical industry. He received the Global Desh Bandhu Gupta Spirit of Lupin Award 2022 for the Value -Passion for Excellence’.

Aurobindo Pharma on February 10 reported a 90.6 percent year-on-year rise in consolidated net profit to INR 936.2 crore for the October-December quarter of the current financial year. The company had a net capex of USD 103 million, including USD 37 million towards its bulk drugs PLI project. The total investment for the PLI project is USD 230 million while in the biosimilar project, it is USD 305 million as of December 31, 2023.

The United States Food and Drug Administration (US FDA) inspected the new injectable facility of Eugia Steriles, the step-down subsidiary of Aurobindo, in Andhra Pradesh.

The inspection closed with three observations and are procedural and will be responded to within the stipulated time, the company said.

Leveraging its large manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and the confidence of its customers, Aurobindo achieved revenue of USD 2.6 billion in FY2017-18. Aurobindo’s 11 units for APIs / intermediates and 15 units (10 in India, 3 in the USA, 1 in Brazil and 1 in Portugal) for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.

A well-integrated pharma company, Aurobindo Pharma features among the Top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports to over 150 countries across the globe with around 90 percent of revenues derived from international operations. Their customers include premium multi-national companies.